Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Crown Bioscience has recently published on the establishment and characterization of a set of NSLCL patient-derived xenograft (PDX) models that harbor non-canonical EGFR mutations.
Subscribe to our email newsletter
EGFR is an important molecular target for drug treatment; however, the lack of relevant experimental models bearing non-canonical EGFR mutations (such as exon 20 insertions) has been a major hurdle in the discovery of new treatments for patients with this specific NSCLC molecular subtype.
CrownBio’s newly established models have been trialed with a range of EGFR inhibitors – including I, II, and III generation TKIs as well as Erbitux – and their poor response to therapy mirrors the clinical outcomes.
With the addition of these models to the large collection of HuPrime PDXs, CrownBio has developed a highly comprehensive panel of NSCLC models with either classic or non-canonical EGFR mutations.
These unique models are available now to clients for testing combination strategies to overcome drug resistance or to develop the next generation of EGFR inhibitors.
"The establishment of these new models demonstrates our commitment to advancing NSCLC drug discovery programs", said Henry Li, Vice President of Translational Oncology at CrownBio.
"Our collection of NSCLC models now includes a selection of both models with classic and non-canonical EGFR mutations, positioning CrownBio at the forefront of drug discovery research for EGFR-mutated NSCLC", continued Li.
CrownBio’s track record of publication on NSCLC research in peer reviewed international scientific journals testifies its commitment to excellence as a provider of preclinical solutions for oncology drug discovery.